Overview

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.
Phase:
Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Cetrorelix
Deslorelin
Follicle Stimulating Hormone
Prolactin Release-Inhibiting Factors
Triptorelin Pamoate